Prognostic Factors in Elderly Patients with Multiple Myeloma Treated with Weekly BortezomibAnne-Laure Couderc1*, Bertrand Coutanceau2, Roger Mouawad2, Bénédicte Mugnier1, Amale Chebib2, Elodie Baudry2, Juliette Spinelli2, Liliana Battaglia2 and Pascal Chaibi2
- *Corresponding Author:
- Anne-Laure Couderc
Hospitals Assistance of Marseille, Marseille, France
Tel: 04 91 38 32 60
E-mail: [email protected]
Received date: February 26, 2016 Accepted date: April 04, 2016 Published date: April 11, 2016
Citation: Couderc AL, Coutanceau B, Mouawad R, Mugnier B, Chebib A, et al. (2016) Prognostic Factors in Elderly Patients with Multiple Myeloma Treated with Weekly Bortezomib. J Integr Oncol 5:162. doi:10.4172/2329-6771.1000162
Copyright: © 2016 Couderc AL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction and objectives: The incidence of multiple myeloma (MM) increases with age. There is a clear decrease in overall survival (OS) in older patients. The purpose of this study was to investigate prognostic factors of MM in this population. Materials and methods: This is an analytic prospective single-center study conducted over 27 months including MM elderly patients treated with weekly subcutaneous bortezomib alone or associated with another chemotherapy. Results: Our work has included 45 patients (median age 84.3 years). Most of them (77.7%) had a PS ≥ 2, 75.6% were undernourished and 57, 1% had a Mini Mental State Examination (MMSE)<26. Haematological grade 3 toxicities were observed in 11% of patients. After 17 months mean follow-up, the median of OS was 18.6 months. In univariate analysis, significant predictors for OS were instrumental activities of daily living (IADL) ≥ 2 (p = 0.003), activities of daily living (ADL)<5 (p = 0.005), the body mass index (BMI)<21 (p = 0.03) and using hospitalization at home unit for bortezomib injections (p = 0.01). In multivariate analysis, significant predictors for OS were ADL<5 (p = 0.005), using hospitalization at home unit (p = 0.007) and IADL ≥ 2 (p = 0.05) Conclusion: In our work, weekly subcutaneous bortezomib was well tolerated. We have shown that functional decline, malnutrition and hospitalization at home unit are predictors of OS. These results lead us to reflect on the need to include these factors in the choice of treatment in elderly patients with MM.